CVRx, Inc. $CVRX Shares Purchased by Rhumbline Advisers

Rhumbline Advisers increased its holdings in shares of CVRx, Inc. (NASDAQ:CVRX) by 13.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,018 shares of the company’s stock after purchasing an additional 2,192 shares during the period. Rhumbline Advisers’ holdings in CVRx were worth $233,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Larson Financial Group LLC acquired a new stake in CVRx during the 1st quarter worth $28,000. Deutsche Bank AG boosted its stake in CVRx by 41.5% during the 1st quarter. Deutsche Bank AG now owns 10,390 shares of the company’s stock worth $127,000 after purchasing an additional 3,048 shares during the period. Tradewinds LLC. boosted its stake in CVRx by 5.8% during the 1st quarter. Tradewinds LLC. now owns 58,011 shares of the company’s stock worth $709,000 after purchasing an additional 3,175 shares during the period. GAMMA Investing LLC boosted its stake in CVRx by 1,469.3% during the 1st quarter. GAMMA Investing LLC now owns 4,598 shares of the company’s stock worth $56,000 after purchasing an additional 4,305 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in CVRx by 12.8% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 41,905 shares of the company’s stock worth $512,000 after purchasing an additional 4,751 shares during the period. Institutional investors and hedge funds own 75.27% of the company’s stock.

CVRx Stock Down 1.9%

CVRX stock opened at $7.32 on Friday. CVRx, Inc. has a one year low of $4.30 and a one year high of $18.55. The stock has a market capitalization of $191.42 million, a PE ratio of -3.49 and a beta of 1.26. The company has a debt-to-equity ratio of 0.85, a quick ratio of 10.78 and a current ratio of 11.99. The company has a fifty day moving average of $7.63 and a 200-day moving average of $7.68.

CVRx (NASDAQ:CVRX) last announced its quarterly earnings results on Monday, August 4th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.05). The company had revenue of $13.59 million during the quarter, compared to analysts’ expectations of $13.22 million. CVRx had a negative net margin of 95.61% and a negative return on equity of 79.31%. CVRx has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts expect that CVRx, Inc. will post -1.91 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CVRX. Cantor Fitzgerald reiterated an “overweight” rating and set a $11.00 price target on shares of CVRx in a research note on Tuesday, August 5th. William Blair upgraded shares of CVRx to a “strong-buy” rating in a research note on Monday, July 7th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $14.00.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.